Evidence map›Paper›PMID 37395359›Full record

ArticleJournal of psychopharmacology (Oxford, England)2023

Psilocybin's effects on cognition and creativity: A scoping review.

Justin N Bonnieux, Baeleigh VanderZwaag, Zahra Premji, Albert Garcia-Romeu, Mauricio A Garcia-Barrera

Abstract readScoping Review
In one paragraph

Article in Journal of psychopharmacology (Oxford, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Cultural Divergence in Psychedelic Use among Medical Students: An ESPAD-Adapted Survey among Poles and Iraqis.European journal of investigation in health, psychology and education · 2024
    Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. High Risk, Low Key: The New Face of Drug Use.Substance use : research and treatment
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Justin N BonnieuxDepartment of Psychology, University of Victoria, Victoria, BC, Canada.ORCID 0000-0001-7376-1183
Baeleigh VanderZwaagDepartment of Psychology, University of Victoria, Victoria, BC, Canada.ORCID 0000-0003-3217-0031
Zahra PremjiUniversity of Victoria Libraries, University of Victoria, Victoria, BC, Canada.ORCID 0000-0002-6899-0528
Albert Garcia-RomeuDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-2182-1644
Mauricio A Garcia-BarreraDepartment of Psychology, University of Victoria, Victoria, BC, Canada.ORCID 0000-0002-4302-4964

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundResearch on psilocybin has become increasingly popular during the current psychedelic renaissance, which began in the early 1990s. Psilocybin's effects on mental health are promising and there are ongoing efforts to investigate its clinical implementation and its effects on cognition.

aimsThe purpose of this study is to report trends in publications, methods, and findings from research examining the effects of psilocybin on cognition and creativity in adults.

methodsWe conducted an Open Science Framework preregistered scoping review, guided by the JBI Manual for Evidence Synthesis, on literature pertaining to psilocybin's effects on cognition and creativity. RESULTS/OUTCOMES: In the 42 included studies, psilocybin was primarily administered orally (83%) in a bodyweight-adjusted manner (74%) to healthy participants (90%). Of the few studies that explicitly reported safety outcomes (26%), only one reported serious adverse reactions. During the acute phase post-intake (i.e., minutes to hours), macrodoses tended to impair cognitive performance and creativity, whereas microdoses tended toward creative enhancement. The few macrodosing studies that included post-acute measures (i.e., 1-85 days) reported primarily null but some positive effects. CONCLUSIONS/

interpretationThis scoping review identified a time-based variation of psilocybin macrodosing effects on cognition and creativity, in which impairment may be observed early post-intake but withdraw over time, and some positive effects may emerge afterward. These findings are limited by methodological concerns and inadequate assessment of long-term effects. We therefore recommend that future psilocybin research be conducted according to existing guidelines and include well-validated measures of cognition and creativity at multiple timepoints.

Indexed as

HallucinogensPsilocybinAdultCognitionCreativityHumansMental HealthHallucinogensPsilocybincognitioncreativityevidence synthesisexecutive functionPsilocybinscoping review

Identifiers

PMID37395359
PMCPMC10350723

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.